Tomaz Crochemore: Surviving Sepsis Campaign 2026 – Are We Still Underestimating Hemostasis?
Tomaz Crochemore, Intensivist at Hospital Moriah, Fellow at the University of Zurich, shared a post on LinkedIn about recent article by Hallie C. Prescott et al., published in Intensive Care Medicine:
“Surviving Sepsis Campaign 2026: Are we still underestimating hemostasis?
The new Surviving Sepsis Campaign 2026 guidelines represent an important step forward in many aspects of sepsis care.
But when it comes to hemostasis, a critical gap remains.
The guidelines:
- Recommend restrictive transfusion strategies
- Strongly support pharmacological VTE prophylaxis
- Address bleeding risk (e.g., stress ulcer prophylaxis)
However…
They do not:
- Recognize coagulopathy phenotypes (thrombotic vs hemorrhagic)
- Address the dynamic transition from SIC to DIC
- Incorporate viscoelastic testing or platelet function assessment
- Provide guidance for individualized hemostatic therapy
- Integrate thrombosis and bleeding into a unified clinical frameworkIn other words:
Coagulation is still treated as fragmented events, not as a dynamic system.
Yet we know:
Sepsis is not only inflammation.
It is immunothrombosis.
Patients evolve from:
- early hypercoagulability and fibrinolysis shutdown
- to late hypocoagulability and bleedingManaging only one side of this spectrum is no longer enough.
We are entering a new era where:
- Hemostasis must be continuously assessed
- Coagulopathy phenotypes must be identified
- Therapy must be individualized and time-sensitive
This is not just progress.
This is a paradigm shift.
This is Precision Hemostatic Medicine.
This is Patient Clot Management.
Give your patient only what they truly need.”
Title: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026
Authors: Hallie C. Prescott, Massimo Antonelli, Waleed Alhazzani, Morten Hylander Møller, Fayez Alshamsi, Luciano C. P. Azevedo, Emilie Belley-Cote, Jan De Waele, Lennie Derde, Joanna C. Dionne, Laura Evans, Hayley B. Gershengorn, Carol L. Hodgson, Kimia Honarmand, Jozef Kesecioglu, Lauralyn McIntyre, Mervyn Mer, Mark E. Nunnally, Simon J. W. Oczkowski, Bram Rochwerg, Olurotimi Olaolu Akinola, Kwame A. Akuamoah-Boateng, Laura Alberto, Derek C. Angus, Yaseen M. Arabi, Elie Azoulay, Maurizio Cecconi, Pauline F. Convocar, Gennaro De Pascale, Kent Doi, Bin Du, Moritoki Egi, Marie-Carmelle Elie-Turenne, Ricard Ferrer, Alison Fox-Robichaud, Craig French, Yonathan Freund, Michelle Ng Gong, Caleb P. Hale, Naomi E. Hammond, Madiha Hashmi, Leo Heunks, Theodore J. Iwashyna, Shevin T. Jacob, Michael Klompas, Arthur Kwizera, Murdoch Leeies, Joanna D. Lejnieks, Mitchell M. Levy, Flavia R. Machado, Marcelo O. Maia, Henry Masur, Ryan C. Maves, Steven McGloughlin, Joanne McPeake, Nicholas M. Mohr, Sheila Nainan Myatra, Marlies Ostermann, Sandra L. Peake, Mathias W. Pletz, Jason A. Roberts, Regis G. Rosa, Robert G. Sawyer, Christa A. Schorr, Steven Q. Simpson, Li Weng, W. Joost Wiersinga, Andrew Rhodes, Craig M. Coopersmith
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 14:52Anticoagulation Management and Outcomes in Patients with Cancer-Associated Small Venous Thromboembolism – JTH
-
Apr 23, 2026, 14:46Mital Jhaveri: Anticoagulant Approval and Uptake Timeline
-
Apr 23, 2026, 14:42Salih Ehsan: Bradykinin-Mediated Transfusion Reactions in Patients on ACE Inhibitors
-
Apr 23, 2026, 14:39Mona Alfaraj: Don’t Miss the Chance to Be Part of the 2nd International Hematology and Hemostasis Conference
-
Apr 23, 2026, 14:11Emerging Contributions to Hemostasis from Recipients of the Christine Lee Young Researcher Awards – WFH
-
Apr 23, 2026, 13:52Joffrey Feriel: A Revised ISTH Definition of Disseminated Intravascular Coagulation
-
Apr 23, 2026, 13:39Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation
-
Apr 23, 2026, 13:35Jecko Thachil: Risk Assessment and Clinical Management of Nephrotic Syndrome–Associated Thrombosis
-
Apr 23, 2026, 12:18Mona Ranade: A Contemporary Framework for Managing Right Heart Thrombus in PE